66th ASH Annual Meeting: 622. Lymphomas: Translational – Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas

Symposia: Lymphomas: Translational – Non-Genetic Oral and Poster Abstracts
Oral

Research, Fundamental Science, Hodgkin lymphoma, Combination therapy, Antibody Therapy, Translational Research, Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Checkpoint Inhibitor, Diseases, Indolent lymphoma, Immune mechanism, Cell expansion, Treatment Considerations, Biological therapies, Aggressive lymphoma, Immunology, Immunotherapy, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Gene editing, Pathogenesis

Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)

Moderators:

Erin M. Parry, MD, PhD, ARRAY(0xee57548) and Tanaya Shree, MD, PhD, Oregon Health and Sciences University

Disclosures:

Shree: Gilead Sciences: Other: Spouse's employment.

This session will describe a number of new novel mechanisms that lymphomas utilise to evade the immune system and will describe therapeutic strategies that might be useful in these settings.

4:00 PM

331

Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma

Katsuyoshi Takata, MD, PhD¹, Hidekazu IIoka²^*, Shuta Tomida, PhD³^*, Yuting Liu⁴^*, Shujiro Okuda⁴^*, Hiroyuki Usuda⁵^*, Takashi Kawasaki⁶^*, Akihiro Kitadate, M.D., Ph.D.⁷, Naoto Takahashi, MD, PhD⁸, Gerben Duns, PhD⁹^*, Yasuharu Sato, PhD¹⁰^*, Christian Steidl, MD, PhD⁹ and Daisuke Ennishi, MD, PhD¹¹

¹Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
²Division of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences, Niigata, Japan., Niigata, Japan
³Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sci, Okayama, JPN
⁴Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Niigata, Japan
⁵Department of Pathology, Nagaoka Red Cross Hospital, Niigata, Japan., Nagaoka, Japan
⁶Department of Pathology, Niigata Cancer Centre Hospital, Niigata, Japan, Niigata, Japan
⁷Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan
⁸Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
⁹Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
¹⁰Department of Molecular Hematopathology, Okayama University, Okayama, Japan
¹¹Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan

4:15 PM

332

Prevention of Antigen Escape By Modulation of Off-Target Tumor Killing in T Cells

Ivan Odak¹^*, Lennart Riemann²^*, Samir Parekh, MD³ and Joshua Brody, MD^1,4^*

¹Icahn School of Medicine at Mount Sinai, New York, NY
²Hannover Medical School, Hannover, Germany
³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁴Tisch Cancer Institute, New York, NY

4:30 PM

333

CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

Ferran Araujo-Ayala^1,2^*, Maria Ros^2,3^*, Mireia Bachiller, PhD⁴^*, Raluca Alexandru⁵^*, Pablo Mozas, MD, PhD⁶^*, Salut Colell⁷^*, Judith Mateos-Jaimez⁸^*, Cristina López, PhD^2,7^*, María Villalba-Esparza, PhD⁵^*, Ferran Nadeu, PhD⁷^*, Andrea Rivero, MD⁹^*, Cèlia Dobaño-López, PhD⁸^*, Juan Garcia Valero, PhD^2,7^*, Neus Serrat, MD, PhD¹⁰^*, Marta Gimenez-Alejandre, PhD⁷^*, Ariadna Giró⁷^*, Daniel J Hodson, MD-PhD¹¹, Armando Lopez-Guillermo, MD^6,12, Elias Campo, MD, PhD¹³, Dolors Colomer^14,15^*, Alba Maiques-Diaz⁷^*, Jose Ignacio Martin-Subero, PhD^7,16^*, Silvia Bea^7,14,17,18^*, Laura Magnano, MD, PhD¹⁹^*, Sonia Guedan²⁰^*, Carlos Eduardo De Andrea, MD, PhD⁵^* and Patricia Perez Galan, PhD^2,8^*

¹Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, ESP
²Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
³Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
⁴Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, ESP
⁵Clínica Universidad de Navarra, Pamplona, Spain
⁶Department of Hematology, ICAMS, Hospital Clínic de Barcelona, Barcelona, Spain
⁷Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain
⁸Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, ESP
⁹Department of Hematology, Hospital Clínic, Barcelona, Barcelona, Spain
¹⁰Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Bacelona, ESP
¹¹Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
¹²University of Barcelona, Barcelona, Spain
¹³Hematopathology Section, Department of Pathology, Hospital Clínic of Barcelona, Barcelona, Spain
¹⁴Hematopathology Section, Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain
¹⁵Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain
¹⁶Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
¹⁷Universitat de Barcelona, Barcelona, Spain
¹⁸Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain
¹⁹Hospital Clínic de Barcelona, Barcelona, Spain
²⁰Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), Barcelona, Spain

4:45 PM

334

B Cell Receptor Inactivation Boosts NK Cell Killing of MYC-Driven Lymphomas

Gabriele Varano, PhD¹, Hiroshi Arima, MD, PhD²^*, Nicara C Parr³^*, Eleonora Sala⁴^*, Marta Mangione⁴^*, Karlo Mladenic⁵^*, Gaia Morello⁶^*, Federica Mainoldi⁷^*, Silvia Brambillasca⁸^*, Adrian Andronache³^*, Vanna Imsirovic⁵^*, Ciro Mercurio⁹^*, Felix Wensveen¹⁰^*, Bojan Polic, MD, PhD¹⁰^*, Mirela Kuka⁴^*, Claudio Tripodo¹¹^* and Stefano Casola, MD, PhD³

¹IFOM-ETS, Milano, Italy
²Kyoto University, Kyoto, JPN
³IFOM-ETS, Milan, Italy
⁴Vita-Salute San Raffaele University, Milan, Italy
⁵University of Rijeka Faculty of Medicine, Rijeka, Croatia
⁶University of Palermo, Palermo, ITA
⁷IFOM ETS-The AIRC Institute of Molecular Oncology, Milano, Italy
⁸Experimental Therapeutics Program, IFOM-ETS, Milan, Italy
⁹IFOM-ETS, Milan, ITA
¹⁰University of Rijeka, Rijeka, Croatia
¹¹University of Palermo, Palermo, Italy

5:00 PM

335

SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion

Cynthia K. Hahn, MD, PhD^1,2,3, Gavin E. Hooper^1,2^*, Alexandra Forman, BSc^1,2,4^*, Gabriela Brunsting Hoffmann²^*, Sam Sadigh, MD^3,5^*, Kun Huang, PhD²^*, Erin M. Parry, MD, PhD^1,2,3, John G. Doench, PhD¹^*, Jeremy M. Simon, PhD^6,7^*, Abner Louissaint, MD, PhD⁸^* and Catherine J. Wu, MD^1,3,9^*

¹Broad Institute of MIT and Harvard, Cambridge, MA
²Dana-Farber Cancer Institute, Boston, MA
³Harvard Medical School, Boston, MA
⁴Harvard Medical School, Cambridge, MA
⁵Department of Pathology, Brigham and Women's Hospital, Boston, MA
⁶Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁷Harvard T.H. Chan School of Public Health, Boston, MA
⁸Massachusetts General Hospital, Boston, MA
⁹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

5:15 PM

336

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Seda S. Tolu, MD¹, Ted B. Piorczynski, PhD², Manuel Pazos II, MS, BS³^*, Brian Estrella, PhD⁴^*, Hua-Jay J Cherng, MD⁵, Barbara Pro, MD⁶ and Jennifer E. Amengual, MD⁷

¹Division of Hematology & Oncology, Columbia University Irving Medical Center, New York City, NY
²Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY
³Columbia University Medical Center, NEW YORK, NY
⁴Division of Hematology and Oncology, Columbia University Irving Medical Center, New York
⁵Division of Hematology & Oncology, Columbia University Irving Medical Center, Long Island City, NY
⁶Lymphoma Program, Division of Hematology & Oncology, Columbia University, New York, NY
⁷Division of Hematology & Oncology, Columbia University Irving Medical Center, New York

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

622.O1.6 622. Lymphomas: Translational – Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas